• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Sometimes, Breaking Up Is Smart to Do

A company that divides itself can unlock value.
By JIM CRAMER Aug 04, 2015 | 11:32 AM EDT
Stocks quotes in this article: HYH, KMB, BAX, RRD, BXLT, SHPG

If you want to create value, sometimes you have to split yourself up into understandable parts and let the chips fall.

We've been huge fans of the "breaking up is easy to do" school of thought, and while there are always companies eager just to shed poorly performing divisions -- here I am thinking of Halyard Health (HYH) being spun off by Kimberly Clark (KMB) at the top of its earnings power -- most of the time managements want to unlock value by making a multidivision company into companies that are easier to understand. (Halyard is part of TheStreet's Action Alerts PLUS portfolio.)

Today we got terrific news from two companies that are determined to bring out value: Baxter (BAX) and RR Donnelley (RRD). For ages, we have been pushing Baxter to split up -- it's even part of a chapter in Get Rich Carefully -- into a slower-growing methodical device company and a fast-ramping biosciences company. About 18 months ago, the Baxter board agreed, and then just at the beginning of June, Baxter gave you a special dividend called Baxalta (BXLT) made up of some dominant blood franchise drugs, including the best compound for hemophilia. Baxter shrewdly kept back a little less than 20% of the new company, in part because the thing's so darned cheap and so good that I think they just wanted to keep a chit in the game.

You got your Baxalta on July 1 and we praised the breakup as a terrific way to get exposure to a well-run albeit niche business. Someone was listening. This morning Shire (SHPG), a very aggressive pharmaceutical company, launched a hostile takeover of Baxalta, coveting the company's rare-disease medicines. The $45.23-a-share bid, at an amazing 36%, sent Baxalta into the stratosphere immediately, although it cooled later on because Baxalta has the tools to fend off the offer. That said, it makes a ton of sense for Shire to pursue it even at a higher price because Shire has a very favorable overseas tax status and can immediately boost its earnings if the deal does close. You would be up 18% from when the spinoff occurred if the deal gets done.

RR Donnelley, the printing company we have so heartily embraced on Mad Money, knocked our socks off today with a decision to split into three companies, all of which make a ton of sense and didn't belong under one roof.

Tom Quinlan, a remarkable CEO, is giving you a financial communications services company, a customized multichannel communications management company and a printing services business.

The company before this new configuration seemed like a confusing mosaic. I like the financial communications business because Donnelley's got a hammerlock on financial communications of public companies. Its multichannel management business can cash in on the rage for brick-and-mortar retailers to go expand into e-commerce.

The most exciting division, though, will be its print services business, which I think can continue to consolidate an industry that prints catalogs and periodicals. Now, I know this business has little growth, but there is ample opportunity for Donnelley to buy other companies in the industry and I think it will do so from the get-go. Consider it Baxalta buying other blood franchise companies rather than being acquired by Shire.

I salute both management teams for recognizing the need to create easy-to-understand structures that immediately unlock value. They are a lesson to other managements that breaking up is both easy and very lucrative, almost immediately, to do.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long HYH.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

There Are Market Bright Spots, but I View the July Rally as a Head Fake

Bret Jensen
Aug 3, 2022 10:30 AM EDT

It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.

A Recession Appears Inevitable, but There Are Still Places to Invest

Bret Jensen
Jul 27, 2022 10:30 AM EDT

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.

Change Healthcare Continues to Knock on a Breakout Level

Bruce Kamich
Jul 25, 2022 11:25 AM EDT

The CHNG chart is at an interesting juncture.

The Healing Process Begins for Cano Health

Bruce Kamich
Jul 21, 2022 1:30 PM EDT

Here's how to approach CANO as the shares have made a bottom formation.

With HCA Healthcare, I'm Getting Healthy Indications

Bruce Kamich
Jul 21, 2022 9:20 AM EDT

The healthcare provider is set to report earnings Friday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login